MX2020005874A - Acidos carbamoil ciclohexilicos n-enlazados a pirazol como antagonistas de receptores del acido lisofosfatidico (lpa). - Google Patents
Acidos carbamoil ciclohexilicos n-enlazados a pirazol como antagonistas de receptores del acido lisofosfatidico (lpa).Info
- Publication number
- MX2020005874A MX2020005874A MX2020005874A MX2020005874A MX2020005874A MX 2020005874 A MX2020005874 A MX 2020005874A MX 2020005874 A MX2020005874 A MX 2020005874A MX 2020005874 A MX2020005874 A MX 2020005874A MX 2020005874 A MX2020005874 A MX 2020005874A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- sub
- alkyl
- haloalkoxy
- alkoxy
- Prior art date
Links
- -1 carbamoyl cyclohexyl acids Chemical class 0.000 title abstract 6
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 14
- 125000003545 alkoxy group Chemical group 0.000 abstract 8
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 8
- 125000003282 alkyl amino group Chemical group 0.000 abstract 7
- 125000000623 heterocyclic group Chemical group 0.000 abstract 7
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 6
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 6
- 125000004994 halo alkoxy alkyl group Chemical group 0.000 abstract 6
- 125000001188 haloalkyl group Chemical group 0.000 abstract 5
- 125000005843 halogen group Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 5
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 150000002431 hydrogen Chemical class 0.000 abstract 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 4
- 125000003342 alkenyl group Chemical group 0.000 abstract 3
- 125000004429 atom Chemical group 0.000 abstract 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000004008 6 membered carbocyclic group Chemical group 0.000 abstract 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000005330 8 membered heterocyclic group Chemical group 0.000 abstract 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 abstract 1
- 108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 229910052805 deuterium Inorganic materials 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención proporciona compuestos de la fórmula (I) o un estereoisómero, tautómero o una sal o solvato farmacéuticamente aceptable de los mismos, en donde X1, X2, X3 y X4 son cada uno independientemente CR6 o N; siempre que no más de dos de X1, X2, X3 o X4 sean N; Q2 es N o NR5a; uno de Q1 y Q3 es CR5, y el otro es N o NR5a; y el círculo discontinuo denota enlaces opcionales que forman un anillo aromático; Y1 es O o NR3; Y2 es -CO-, -SO2-, o -S(O(NH)-; Y3 es O o NR4a; siempre que (1) Y1 e Y3 no sean O, y (2) cuando Y2 sea C(O), Y1 no sea O; L es un enlace covalente o alquileno C1-4 sustituido con 0 a 4 R7; R1 es (-CH2)aR9; a es un número entero de 0 o 1; R2 es cada uno independientemente halo, ciano, hidroxilo, amino, alquilo C1-6, cicloalquilo C3-6, heterociclilo C4-6, alquilamino, haloalquilo, hidroxialquilo, aminoalquilo, alcoxi, alcoxialquilo, haloalcoxialquilo o haloalcoxi; n es un entero de 0, 1 o 2; R3 y R4a son independientemente hidrógeno, alquilo C1-6, haloalquilo, hidroxialquilo, aminoalquilo, alcoxialquilo, haloalcoxialquilo, alcoxi o haloalcoxi; R4 es alquilo C1-10, haloalquilo C1-10, alquilo C1-10 deuterado, alquenilo C1-10, cicloalquilo C3-8, arilo de 6 a 10 elementos, heterociclilo de 3 a 8 elementos, -(alquileno C1-6) (cicloalquilo C3-8), -(alquileno C1-6)-(arilo de 6 a 10 elementos), -(alquileno C1- 6)-(heterociclilo de 3 a 8 elementos), o -(alquileno C1-6)- (heteroarilo de 5 a 6 elementos); en donde cada uno de los alquilo, alquileno, alquenilo, cicloalquilo, arilo, heterociclilo y heteroarilo, por sí mismos o como parte de otra porción, están sustituidos independientemente con 0 a 3 R; o alternativamente, R3 y R4, tomados junto con los átomos de N y O a los que están unidos, forman una porción de anillo heterocíclico de 4 a 9 elementos que está sustituido con 0 a 3 R8; o alternativamente, (R3 y R5a) o (R3 y R5), tomados junto con los átomos a los que están unidos, forman una porción de anillo heterocíclico de 5 a 8 elementos que está sustituido con 0 a 3 R8; R5a es hidrógeno, alquilo C1-6, alquilamino, haloalquilo, hidroxialquilo, aminoalquilo, alcoxialquilo, haloalcoxialquilo, alcoxi o haloalcoxi; R5 y R6 son cada uno independientemente hidrógeno, halo, ciano, hidroxilo, amino, alquilo, alquilamino, haloalquilo, hidroxialquilo, aminoalquilo, alcoxialquilo, haloalcoxialquilo, alcoxi o haloalcoxi; R7 es halo, oxo, ciano, hidroxilo, amino, alquilo C1-6, cicloalquilo C3-6, heterociclilo C4-6, alquilamino, haloalquilo, hidroxialquilo, aminoalquilo, alcoxialquilo, haloalcoxialquilo, alcoxi o haloalcoxi; R8 son cada uno independientemente deuterio, halo, hidroxilo, amino, ciano, alquilo C1-6, alquilo C1-6 deuterado, alquenilo C2-6, alquinilo C2-6, alquilamino, haloalquilo, hidroxialquilo, aminoalquilo, alcoxialquilo, haloalcoxialquilo, alcoxi, haloalcoxi, fenilo o heteroarilo de 5 a 6 elementos; o alternativamente, dos R8, tomados junto con el(los) átomo(s) al(a los) que están unidos, forman un anillo carbocíclico de 3 a 6 elementos o un anillo heterocíclico de 3 a 6 elementos, cada uno de los cuales está independientemente sustituido con 0 a 3 R12; R9 se selecciona de -CN, -C(O)OR10, -C(O)NR11aR11b, -CO-NH-CO-Re, -CO-NH-SO2-Re, -CO-NH-SO-Re, -SO2- OH, -SO2-NH-CO-Re, -P(O)(OH)2, tetrazol-5-ilo, -CH-CO-NH-CORe, -CH2-CO-NH-SO2-Re, -CH2-CO-NH-SO-Re, -CH2-SO2-OH, -CH2-SO2- NH-CO-Re, -CH2-P(O)(OH)2, tetrazol-5-ilmetileno; Re es alquilo C1-6, cicloalquilo C3-6, haloalquilo, hidroxialquilo, aminoalquilo, alcoxialquilo o haloalcoxialquilo; R10 es hidrógeno o alquilo C1-10; y R11a y R11b son cada uno independientemente hidrógeno, alquilo C1-6, cicloalquilo C3-6, heterociclilo C4-6, alquilamino, haloalquilo, hidroxialquilo, aminoalquilo, alcoxialquilo, haloalcoxialquilo, alcoxi o haloalcoxi; y R12 es halo, ciano, hidroxilo, amino, alquilo C1-6, alquilamino, haloalquilo, hidroxialquilo, aminoalquilo, alcoxialquilo, haloalcoxialquilo, alcoxi, haloalcoxi, fenilo o heteroarilo de 5 a 6 elementos. Estos compuestos son inhibidores selectivos del receptor de LPA.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762607541P | 2017-12-19 | 2017-12-19 | |
| PCT/US2018/066110 WO2019126085A1 (en) | 2017-12-19 | 2018-12-18 | Pyrazole n-linked carbamoyl cyclohexyl acids as lpa antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020005874A true MX2020005874A (es) | 2020-08-13 |
Family
ID=65003575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020005874A MX2020005874A (es) | 2017-12-19 | 2018-12-18 | Acidos carbamoil ciclohexilicos n-enlazados a pirazol como antagonistas de receptores del acido lisofosfatidico (lpa). |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11384067B2 (es) |
| EP (1) | EP3728216B1 (es) |
| JP (1) | JP7301839B2 (es) |
| KR (1) | KR102698386B1 (es) |
| CN (1) | CN111699180B (es) |
| AU (1) | AU2018388482A1 (es) |
| BR (1) | BR112020011953A2 (es) |
| CA (1) | CA3085347A1 (es) |
| EA (1) | EA202091500A1 (es) |
| ES (1) | ES2962367T3 (es) |
| IL (1) | IL275361A (es) |
| MX (1) | MX2020005874A (es) |
| SG (1) | SG11202005701VA (es) |
| WO (1) | WO2019126085A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR108838A1 (es) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
| CN112041304B (zh) * | 2017-12-19 | 2025-03-07 | 百时美施贵宝公司 | 作为lpa拮抗剂的异噁唑n-连接的氨基甲酰基环己基酸 |
| TWI830713B (zh) | 2017-12-19 | 2024-02-01 | 美商必治妥美雅史谷比公司 | 作為lpa拮抗劑之三唑n-連接之胺甲醯基環己基酸 |
| JP7412424B2 (ja) * | 2018-09-18 | 2024-01-12 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのオキサビシクロ酸 |
| JP7427658B2 (ja) | 2018-09-18 | 2024-02-05 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのシクロペンチル酸 |
| CN111434655A (zh) | 2019-01-15 | 2020-07-21 | 武汉朗来科技发展有限公司 | 溶血磷脂酸受体拮抗剂及其制备方法 |
| KR102775995B1 (ko) | 2019-11-15 | 2025-03-11 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제로서의 트라이아졸 카르바메이트 피리딜 설폰아미드 및 이의 용도 |
| TWI843503B (zh) | 2020-06-03 | 2024-05-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| CA3185689A1 (en) | 2020-06-03 | 2021-12-09 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| WO2022100625A1 (zh) * | 2020-11-10 | 2022-05-19 | 武汉人福创新药物研发中心有限公司 | 氮取代氨基碳酸酯噻吩类化合物及其用途 |
| WO2022174882A1 (en) * | 2021-02-16 | 2022-08-25 | Chiesi Farmaceutici S.P.A. | 5-membered heterocyclyl carbamate derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors |
| AU2022273631B2 (en) * | 2021-05-11 | 2025-04-17 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| WO2022241023A1 (en) | 2021-05-13 | 2022-11-17 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| CN118541360A (zh) | 2021-12-08 | 2024-08-23 | 吉利德科学公司 | Lpa受体拮抗剂及其用途 |
| TW202342017A (zh) | 2022-02-25 | 2023-11-01 | 美商洛子峰生物有限公司 | 用於治療與ｌｐａ受體活性相關的病狀的化合物及組合物 |
| WO2025051266A1 (zh) * | 2023-09-08 | 2025-03-13 | 西藏海思科制药有限公司 | 杂芳环衍生物的lpar1拮抗剂及其用途 |
| CN117024409A (zh) * | 2023-10-10 | 2023-11-10 | 药康众拓(北京)医药科技有限公司 | 氘代lpa1抑制剂化合物及其用途 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE447970T1 (de) | 2001-02-08 | 2009-11-15 | Ono Pharmaceutical Co | Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors |
| US7432271B2 (en) * | 2003-09-02 | 2008-10-07 | Bristol-Myers Squibb Company | Pyrazolyl inhibitors of 15-lipoxygenase |
| DE102004038403B4 (de) | 2004-08-07 | 2006-08-31 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten |
| JP2013501064A (ja) | 2009-08-04 | 2013-01-10 | アミラ ファーマシューティカルス，インコーポレーテッド | リゾホスファチジン酸受容体アンタゴニストとしての化合物 |
| GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
| EA201390821A1 (ru) | 2010-12-07 | 2013-10-30 | Амира Фармасьютикалс, Инк. | Антагонисты рецепторов лизофосфатидной кислоты и их применение |
| US8785442B2 (en) | 2011-01-30 | 2014-07-22 | Curegenix, Inc. | Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof |
| WO2012138648A1 (en) | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
| WO2013070879A1 (en) | 2011-11-10 | 2013-05-16 | Bristol-Myers Squibb Company | Methods for treating spinal cord injury with lpa receptor antagonists |
| WO2013085824A1 (en) | 2011-12-04 | 2013-06-13 | Angion Biomedica Corp. | Small molecule anti-fibrotic compounds and uses thereof |
| KR20150021057A (ko) | 2012-06-20 | 2015-02-27 | 에프. 호프만-라 로슈 아게 | Lpar 길항제로서의 n-알킬트라이아졸 화합물 |
| US20150133512A1 (en) | 2012-06-20 | 2015-05-14 | Hoffmann-La Roche Inc, | N-aryltriazole compounds as lpar antagonists |
| CN104411690A (zh) * | 2012-06-20 | 2015-03-11 | 霍夫曼-拉罗奇有限公司 | 作为lpar拮抗剂的取代的吡唑化合物 |
| AU2014232383B2 (en) * | 2013-03-15 | 2019-01-17 | Epigen Biosciences, Inc. | Heterocyclic compounds useful in the treatment of disease |
| WO2016044556A2 (en) * | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| AR108838A1 (es) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
| EP3728240B1 (en) * | 2017-12-19 | 2022-06-29 | Bristol-Myers Squibb Company | Isoxazole o-linked carbamoyl cyclohexyl acids as lpa antagonists |
| TWI830713B (zh) | 2017-12-19 | 2024-02-01 | 美商必治妥美雅史谷比公司 | 作為lpa拮抗劑之三唑n-連接之胺甲醯基環己基酸 |
| CN112041302B (zh) * | 2017-12-19 | 2024-11-19 | 百时美施贵宝公司 | 作为lpa拮抗剂的吡唑o-连接的氨基甲酰基环己基酸 |
| ES2924704T3 (es) * | 2017-12-19 | 2022-10-10 | Bristol Myers Squibb Co | Pirazol azoles del ácido ciclohexílico como antagonistas de LPA |
-
2018
- 2018-12-18 ES ES18830676T patent/ES2962367T3/es active Active
- 2018-12-18 SG SG11202005701VA patent/SG11202005701VA/en unknown
- 2018-12-18 AU AU2018388482A patent/AU2018388482A1/en not_active Abandoned
- 2018-12-18 KR KR1020207020528A patent/KR102698386B1/ko active Active
- 2018-12-18 US US16/954,310 patent/US11384067B2/en active Active
- 2018-12-18 JP JP2020533674A patent/JP7301839B2/ja active Active
- 2018-12-18 CA CA3085347A patent/CA3085347A1/en not_active Abandoned
- 2018-12-18 BR BR112020011953-9A patent/BR112020011953A2/pt not_active Application Discontinuation
- 2018-12-18 MX MX2020005874A patent/MX2020005874A/es unknown
- 2018-12-18 EP EP18830676.5A patent/EP3728216B1/en active Active
- 2018-12-18 CN CN201880089037.2A patent/CN111699180B/zh active Active
- 2018-12-18 WO PCT/US2018/066110 patent/WO2019126085A1/en not_active Ceased
- 2018-12-18 EA EA202091500A patent/EA202091500A1/ru unknown
-
2020
- 2020-06-14 IL IL275361A patent/IL275361A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN111699180A (zh) | 2020-09-22 |
| CA3085347A1 (en) | 2019-06-27 |
| JP2021507895A (ja) | 2021-02-25 |
| KR20200100712A (ko) | 2020-08-26 |
| EP3728216A1 (en) | 2020-10-28 |
| AU2018388482A1 (en) | 2020-07-30 |
| KR102698386B1 (ko) | 2024-08-22 |
| IL275361A (en) | 2020-07-30 |
| EP3728216B1 (en) | 2023-09-06 |
| BR112020011953A2 (pt) | 2020-11-17 |
| US11384067B2 (en) | 2022-07-12 |
| JP7301839B2 (ja) | 2023-07-03 |
| ES2962367T3 (es) | 2024-03-18 |
| WO2019126085A1 (en) | 2019-06-27 |
| SG11202005701VA (en) | 2020-07-29 |
| EA202091500A1 (ru) | 2020-09-14 |
| CN111699180B (zh) | 2024-11-29 |
| US20210087173A1 (en) | 2021-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020005874A (es) | Acidos carbamoil ciclohexilicos n-enlazados a pirazol como antagonistas de receptores del acido lisofosfatidico (lpa). | |
| MX2021009763A (es) | Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos. | |
| RU2500680C2 (ru) | Новые замещенные пиридин-2-оны и пиридазин-3-оны | |
| AR113964A1 (es) | Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa | |
| MX2020005363A (es) | Compuestos heterociclicos como inhibidores de prmt5. | |
| UY38296A (es) | Derivados de 3–(5–amino–1–oxoisoindolin–2–il)piperidin–2,6–diona y sus usos | |
| SA518391518B1 (ar) | مشتقات n-] 2-(1- بنزيل ببريدين-4-يل) إيثيل[ -4-(بيرازين-2-يل)-ببرازين-1- كربوكساميد ومركبات متصلة بها كمضادات مستقبلة المسكارين 4 (m4) لمعالجة أمراض عصبية | |
| AR082681A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR082888A1 (es) | Compuestos de piridina para la inhibicion de nampt | |
| MX2014015501A (es) | Carboxamidas heterociclicas fungicidas. | |
| PH12017501652A1 (en) | Kv1.3 inhibitors and their medical application | |
| JP2016506960A5 (es) | ||
| HRP20171453T1 (hr) | Derivati imidazotiadiazola i imidazopirazina kao inhibitori proteazom aktiviranog receptora 4 (par4) za liječenje agregacije trombocita | |
| IN2014DN10806A (es) | ||
| RU2015121431A (ru) | Замещенные производные индол-5-ола и их терапевтическое применение | |
| MX2021006544A (es) | Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer. | |
| AR099379A1 (es) | Compuestos tricíclicos como agentes antineoplásicos | |
| IL272762B1 (en) | Compressed heterocyclics as BCL-2 inhibitors for the treatment of neoplastic diseases | |
| AR094346A1 (es) | Derivados de azaindol como inhibidores de las proteína quinasas | |
| RU2016135922A (ru) | Терапевтические соединения и композиции | |
| MX2015008971A (es) | Derivados de pirimidina pirido- o pirrolo-fusionados como inhibidores de autotaxina para tratar dolor. | |
| PE20212253A1 (es) | Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd) | |
| WO2008046087A3 (en) | Spiro compounds and their uses as therapeutic agents | |
| EA201990902A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| CR20200418A (es) | Inhibidores de orginasa y sus mètodos de uso antecedentes |